Cro services in
CNS / Brain Imaging
Our imaging services provide a new innovative strategy for characterizing CNS disease models, mapping drug targets and evaluating treatment effects. We use fully automated light-sheet microscopy for 3D imaging of the intact brain at single cell resolution.
Why Gubra?
-
End-to-end light-sheet service provider
-
Fully automated immunolabeling and clearing
-
AI-assisted mapping and quantification
- Cloud-based interactive brain data viewer
- Approximately 2.5 months from study to data presentation


Consult with Jacob Hecksher-Sørensen
Director, Scientific Sales
Get expert advice on whole-brain imaging and discuss how to design your next study.
Imaging services that enable quantification and visualization of your drug’s effects
Gubra is changing the future of preclinical CNS drug discovery with an industry-leading 3D imaging platform. Explore how our whole-brain imaging pipeline can visualize drug distribution, map drug targets and quantify treatment outcomes in unprecedented detail.
Main Offerings
Quantitative
whole brain imaging
Anatomical
reference mapping
Automated
stereotactic surgery
Complete
pharmacological solutions
Multiplexed
IHC & ISH endpoints
Gene
& cell therapy
Complex 3D imaging data to clear interpretable data
Atlas-defined CNS imaging endpoints

Parkinson’s Disease
- Quantification of total dopaminergic neuron numbers
- Mapping and quantifying α-synuclein aggregate spreading Neuroinflammation markers
- Markers of axon architecture
- Monitoring progression of motor deficits

Alzheimer’s Disease
- Quantification of amyloid plaque burden
- Mapping cerebral amyloid angiopathy
- Visualization of drug distribution and BBB penetration
- Neuronal loss and brain atrophy

CNS activation
- Whole-brain activation (c-Fos) maps
- Voxel-based statistical maps for subanatomical responses
- Comparative c-Fos maps for benchmarking drugs

Drug distribution
- Visualization and mapping of CNS drug distribution
- Parenchyma vs vascular drug distribution
- Mapping and quantifying BBB penetrance

Gene therapy
- Distribution of AAV and non-viral gene delivery systems
- Visualization of siRNA distribution
- Validation and quantification of target knockdown/overexpression

Gene expression
- Whole-brain in situ hybridization for gene expression maps
- Quantification of drug target expression at single-nuclei resolution
- Delineating gene expression changes in disease models

Related pages
For further information
Contact us
Gubra
Hørsholm Kongevej 11B
2970 Hørsholm
Denmark
+45 3152 2650